PORTER, David L.
New Eng. J. Med., 365, 725-733, 2011.
Carl H. June and colleagues proved that the ‘concept’ of CAR T-cell therapy developed by them, was a very promising and viable alternative in specific recalcitrant cancers. They showed that their novel in-vitro-created molecular cocktail of agents including T-cells, chimeric antigen receptors and other esoteric ingredients (T-cells engineered in the lab to target the specific CD19 in cancerous B cells delivered into the patient in a HIV lentiviral vector), met the following requirements:
Subjects: ONCOLOGY & CANCER › Leukemia